# The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients

> **NCT05579418** · PHASE4 · UNKNOWN · sponsor: **Hamad Medical Corporation** · enrollment: 350 (estimated)

## Conditions studied

- STEMI
- Dyslipidemias

## Interventions

- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT05579418
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2022-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05579418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05579418, "The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05579418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*